

Table 9.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Liver Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	4,516	4,751	4,997	5,196	5,332	5,673	6,171	6,444	6,651	6,494
Tx with Antirejection Treatments	1,184	1,466	1,498	1,418	1,300	1,041	994	1,036	823	728
Antibodies										
Any in Category	13.1%	12.5%	14.5%	16.7%	17.5%	17.8%	21.2%	14.9%	15.1%	17.2%
Atgam/NRATG/NRATS	1.4%	0.7%	0.5%	0.5%	0.6%	0.8%	0.8%	1.1%	0.5%	0.5%
OKT3	9.7%	6.8%	6.2%	6.7%	5.9%	5.4%	5.7%	4.5%	3.6%	6.0%
Thymoglobulin	0.3%	1.4%	3.2%	5.1%	5.6%	7.0%	11.3%	7.5%	8.9%	9.5%
Zenapax	0.9%	1.7%	2.4%	1.6%	1.9%	1.3%	3.4%	0.8%	0.9%	1.0%
Simulect	1.2%	3.1%	3.1%	4.2%	4.0%	3.0%	0.8%	0.9%	0.6%	0.4%
Campath	0.0%	0.0%	0.0%	0.0%	0.6%	2.0%	1.4%	1.0%	1.3%	1.6%
Corticosteroids										
Any in Category	87.3%	89.5%	90.8%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%	92.7%
Steroids	87.3%	89.5%	90.8%	89.1%	90.3%	91.6%	88.5%	91.5%	92.2%	92.7%
Antimetabolites										
Any in Category	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.3%	0.1%	0.1%
Cytosan	0.3%	0.2%	0.1%	0.1%	0.0%	0.1%	0.0%	0.2%	0.1%	0.1%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.